2-(3,3-diethylazetidin-1-yl)-N-[3,5-difluoro-4-(oxan-3-yloxy)phenyl]-5-ethyl-1,3-oxazole-4-carboxamide
C24H31F2N3O4 — CID 170720444
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-(3,3-diethylazetidin-1-yl)-N-[3,5-difluoro-4-(oxan-3-yloxy)phenyl]-5-ethyl-1,3-oxazole-4-carboxamide
2-(3,3-diethylazetidin-1-yl)-N-[3,5-difluoro-4-(oxan-3-yloxy)phenyl]-5-ethyl-1,3-oxazole-4-carboxamide (PubChem CID 170720444) has the molecular formula C24H31F2N3O4 and a molecular weight of 463.53 g/mol. Its IUPAC name is 2-(3,3-diethylazetidin-1-yl)-N-[3,5-difluoro-4-(oxan-3-yloxy)phenyl]-5-ethyl-1,3-oxazole-4-carboxamide.
Molecular Properties
| Compound Name | 2-(3,3-diethylazetidin-1-yl)-N-[3,5-difluoro-4-(oxan-3-yloxy)phenyl]-5-ethyl-1,3-oxazole-4-carboxamide |
|---|---|
| PubChem CID | 170720444 |
| Molecular Formula | C24H31F2N3O4 |
| Molecular Weight | 463.53 g/mol |
| Exact Mass | 463.23 |
| IUPAC Name | 2-(3,3-diethylazetidin-1-yl)-N-[3,5-difluoro-4-(oxan-3-yloxy)phenyl]-5-ethyl-1,3-oxazole-4-carboxamide |
| SMILES | CCc1oc(N2CC(CC)(CC)C2)nc1C(=O)Nc1cc(F)c(OC2CCCOC2)c(F)c1 |
| InChI | InChI=1S/C24H31F2N3O4/c1-4-19-20(28-23(33-19)29-13-24(5-2,6-3)14-29)22(30)27-15-10-17(25)21(18(26)11-15)32-16-8-7-9-31-12-16/h10-11,16H,4-9,12-14H2,1-3H3,(H,27,30) |
| InChIKey | XXMDZXCSDVQWBX-UHFFFAOYSA-N |
| XLogP | 4.95 |
| TPSA | 76.83 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 463.53 |
| LogP ≤ 5 | 4.95 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 170720444 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.